News | February 20, 2022
GSK pauses phase III RSV maternal vaccine candidate programme
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Revenue increased 11.4 per cent to Rs. 8,545 crore
Subscribe To Our Newsletter & Stay Updated
